Valsts: Singapūra
Valoda: angļu
Klimata pārmaiņas: HSA (Health Sciences Authority)
SALBUTAMOL SULPHATE EQV SALBUTAMOL
ORION PHARMA (SG) PTE. LTD.
R03AC02
200 mcg/dose
POWDER, METERED
SALBUTAMOL SULPHATE EQV SALBUTAMOL 200 mcg/dose
RESPIRATORY (INHALATION)
Prescription Only
ORION CORPORATION (ESPOO PLANT)
ACTIVE
1996-04-24
1. NAME OF THE MEDICINAL PRODUCT BUVENTOL EASYHALER ™ 100 MCG/ DOSE INHALATION POWDER BUVENTOL EASYHALER ™ 200 MCG/ DOSE INHALATION POWDER 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Buventol Easyhaler ™ is an inhalation powder packed into a multiple dose powder inhaler from which the patient can accurately deliver the individual drug doses. It is for oral inhalation. _Buventol Easyhaler_ ™ _ 100 mcg/ dose Inhalation Powder_ : The product contains salbutamol sulphate equivalent to 100 mcg of salbutamol per metered dose. The dose, which the patient gets through the mouthpiece of the device is 90 mcg of salbutamol. _Buventol Easyhaler_ ™ _ 200 mcg/ dose Inhalation Powder_ : The product contains salbutamol sulphate equivalent to 200 mcg of salbutamol per metered dose. The dose, which the patient gets through the mouthpiece of the device is 180 mcg of salbutamol. The Buventol Easyhaler ™ multiple dose powder inhaler contains 200 doses of finely powdered salbutamol sulphate mixed in a small quantity of lactose. The amount of drug received by the patient (90 or 180 mcg/dose) corresponds to that from salbutamol inhalation aerosol. The dose to be inhaled is released from the container by pressing the device between the thumb and forefinger. This is followed by inhalation through the device. As a result, salbutamol particles are transferred to their target, the lungs. Use of the Buventol Easyhaler ™ does not require coordination of actuation of the dose and inhalation. 3. PHARMACEUTICAL FORMS Inhalation powder. White or almost white powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Symptomatic treatment of acute asthma attack. • Prevention of exercise-induced bronchospasm. • Symptomatic treatment of bronchial asthma and other conditions, such as bronchitis and emphysema, associated with reversible airways obstruction. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The preparation is intended for oral inhalation only. This preparation is particularly useful for patients who are unable to use mete Izlasiet visu dokumentu